Patrick L Heilman1, Ernest W Wang2, Mechelle M Lewis2,3, Stanislaw Krzyzanowski1, Colt D Capan1, Amanda R Burmeister1, Guangwei Du2, Martha L Escobar Galvis1, Patrik Brundin1, Xuemei Huang2,3,4,5,6, Lena Brundin1,7. 1. Center for Neurodegenerative Science, Van Andel Institute, Grand Rapids, Michigan, USA. 2. Department of Neurology, Penn State University-Milton S. Hershey Medical Center, Hersey Pennsylvania, USA. 3. Department of Pharmacology, Penn State University-Milton S. Hershey Medical Center, Hersey Pennsylvania, USA. 4. Department of Neurosurgery, Penn State University-Milton S. Hershey Medical Center, Hersey Pennsylvania, USA. 5. Department of Radiology, Penn State University-Milton S. Hershey Medical Center, Hersey Pennsylvania, USA. 6. Department of Kinesiology, Penn State University-Milton S. Hershey Medical Center, Hersey Pennsylvania, USA. 7. Division of Psychiatry & Behavioral Medicine, Michigan State University College of Human Medicine, Grand Rapids, Michigan, USA.
Abstract
BACKGROUND: The objective of this study was to determine whether neurotoxic kynurenine metabolites, induced by inflammation, in plasma and cerebrospinal fluid (CSF) are associated with symptom severity and nigral pathology in Parkinson's disease (PD). METHODS: Clinical and MRI data were obtained from 97 PD and 89 controls. We used ultra-performance liquid chromatography to quantify kynurenine metabolites and high-sensitivity multiplex assays to quantify inflammation in plasma and CSF. We evaluated group-wise differences as well as associations between the biomarkers, motor and nonmotor symptoms, and nigral R2* (MRI metric reflecting iron content). RESULTS: PD subjects had >100% higher 3-hydroxykynurenine and 14% lower 3-hydroxyanthranilic acid in plasma. The 3-HK in plasma was closely associated with both symptom severity and disease duration. PD subjects also had 23% lower kynurenic acid in the CSF. Higher CSF levels of the excitotoxin quinolinic acid were associated with more severe symptoms, whereas lower levels of the neuroprotective kynurenic acid were linked to olfactory deficits. An elevated quinolinic acid/picolinic acid ratio in the CSF correlated with higher R2* values in the substantia nigra in the entire cohort. Plasma C-reactive protein and serum amyloid alpha were associated with signs of increased kynurenine pathway activity in the CSF of PD patients, but not in controls. CONCLUSIONS: In PD, the kynurenine pathway metabolite levels are altered in both the periphery and the central nervous system, and these changes are associated with symptom severity. Replication studies are warranted in other cohorts, and these can also explore if kynurenine metabolites might be PD biomarkers and/or are involved in PD pathogenesis.
BACKGROUND: The objective of this study was to determine whether neurotoxickynurenine metabolites, induced by inflammation, in plasma and cerebrospinal fluid (CSF) are associated with symptom severity and nigral pathology in Parkinson's disease (PD). METHODS: Clinical and MRI data were obtained from 97 PD and 89 controls. We used ultra-performance liquid chromatography to quantify kynurenine metabolites and high-sensitivity multiplex assays to quantify inflammation in plasma and CSF. We evaluated group-wise differences as well as associations between the biomarkers, motor and nonmotor symptoms, and nigral R2* (MRI metric reflecting iron content). RESULTS:PD subjects had >100% higher 3-hydroxykynurenine and 14% lower 3-hydroxyanthranilic acid in plasma. The 3-HK in plasma was closely associated with both symptom severity and disease duration. PD subjects also had 23% lower kynurenic acid in the CSF. Higher CSF levels of the excitotoxin quinolinic acid were associated with more severe symptoms, whereas lower levels of the neuroprotective kynurenic acid were linked to olfactory deficits. An elevated quinolinic acid/picolinic acid ratio in the CSF correlated with higher R2* values in the substantia nigra in the entire cohort. Plasma C-reactive protein and serum amyloid alpha were associated with signs of increased kynurenine pathway activity in the CSF of PDpatients, but not in controls. CONCLUSIONS: In PD, the kynurenine pathway metabolite levels are altered in both the periphery and the central nervous system, and these changes are associated with symptom severity. Replication studies are warranted in other cohorts, and these can also explore if kynurenine metabolites might be PD biomarkers and/or are involved in PD pathogenesis.
Authors: Jose Felix Martí-Massó; Alberto Bergareche; Vladimir Makarov; Javier Ruiz-Martinez; Ana Gorostidi; Adolfo López de Munain; Juan Jose Poza; Pasquale Striano; Joseph D Buxbaum; Coro Paisán-Ruiz Journal: J Mol Med (Berl) Date: 2013-08-20 Impact factor: 4.599
Authors: Cecilie Bay-Richter; Klas R Linderholm; Chai K Lim; Martin Samuelsson; Lil Träskman-Bendz; Gilles J Guillemin; Sophie Erhardt; Lena Brundin Journal: Brain Behav Immun Date: 2014-08-12 Impact factor: 7.217
Authors: Jesper F Havelund; Andreas D Andersen; Michael Binzer; Morten Blaabjerg; Niels H H Heegaard; Egon Stenager; Nils J Faergeman; Jan Bert Gramsbergen Journal: J Neurochem Date: 2017-07-11 Impact factor: 5.372
Authors: Guangwei Du; Mechelle M Lewis; Christopher Sica; Lu He; James R Connor; Lan Kong; Richard B Mailman; Xuemei Huang Journal: Mov Disord Date: 2018-05-14 Impact factor: 10.338
Authors: Jennifer S A M Reijnders; Uwe Ehrt; Wim E J Weber; Dag Aarsland; Albert F G Leentjens Journal: Mov Disord Date: 2008-01-30 Impact factor: 10.338
Authors: Freek J H Sorgdrager; Yannick Vermeiren; Martijn Van Faassen; Claude van der Ley; Ellen A A Nollen; Ido P Kema; Peter P De Deyn Journal: J Neurochem Date: 2019-08-25 Impact factor: 5.372
Authors: Elena A Ostrakhovitch; Eun-Suk Song; Jessica K A Macedo; Matthew S Gentry; Jorge E Quintero; Craig van Horne; Tritia R Yamasaki Journal: Neurosci Lett Date: 2021-12-28 Impact factor: 3.046
Authors: Jonathan Savitz; Bart N Ford; Rayus Kuplicki; Sahib Khalsa; T Kent Teague; Martin P Paulus Journal: Psychopharmacology (Berl) Date: 2022-10-22 Impact factor: 4.415
Authors: Peipei Li; Bryan A Killinger; Elizabeth Ensink; Ian Beddows; Ali Yilmaz; Noah Lubben; Jared Lamp; Meghan Schilthuis; Irving E Vega; Randy Woltjer; J Andrew Pospisilik; Patrik Brundin; Lena Brundin; Stewart F Graham; Viviane Labrie Journal: Metabolites Date: 2021-01-04
Authors: Timothy B Meier; Lezlie España; Morgan E Nitta; T Kent Teague; Benjamin L Brett; Lindsay D Nelson; Michael A McCrea; Jonathan Savitz Journal: Brain Behav Immun Date: 2020-11-08 Impact factor: 7.217
Authors: George Zhang Wei; Katherine A Martin; Peter Yuli Xing; Ruchi Agrawal; Luke Whiley; Thomas K Wood; Sophia Hejndorf; Yong Zhi Ng; Jeremy Zhi Yan Low; Janet Rossant; Robert Nechanitzky; Elaine Holmes; Jeremy K Nicholson; Eng-King Tan; Paul M Matthews; Sven Pettersson Journal: Proc Natl Acad Sci U S A Date: 2021-07-06 Impact factor: 11.205